カタログ製品コード : C-EK12272
Human BID ELISA kit
24T | ¥92,200 | (¥3,842/T) (税別) |
48T | ¥106,200 | (¥2,213/T) (税別) |
96T | ¥115,000 | (¥1,198/T) (税別) |
標準納期 : 2週間 |
カタログ製品コード : C-EK12272
Human BID ELISA kit
24T | ¥92,200 | (¥3,842/T) (税別) |
48T | ¥106,200 | (¥2,213/T) (税別) |
96T | ¥115,000 | (¥1,198/T) (税別) |
標準納期 : 2週間 |
メーカー名 | 遺伝子名 | 種交差性 | 測定範囲 | サンプル量 | 適用サンプル | ドキュメント |
---|---|---|---|---|---|---|
MultiSciences | BID | Human | 15.63 - 1000 pg/ml | 20 μl (prediluted) | 血清、血漿、細胞培養上清 |
■保存方法 :
キットは未開封の場合、4℃で保管すること。 開封後は標準溶液を-20℃で保存し、他の試薬は4℃で保存すること。
■構成内容 :
96-well polystyrene microplate coated with a monoclonal antibody against BID |
Human BID Standard, lyophilized |
BID Detect Antibody |
Assay Buffer (10×) |
Substrate (TMB) |
Stop Solution |
Washing Buffer (20×) |
Plate Covers |
■キーワード :
Homo sapiens,Human,BH3-interacting domain death agonist,p22 BID,BID,BID
■ターゲット情報 :
This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human BID. The Human BID ELISA is for research use only. Not for diagnostic or therapeutic procedures.
The BH3 interacting domain death agonist (BID), containing only the BH3 domain, is a pro-apoptotic member of the Bcl-2 protein family. BID is important to cell death mediated by Bcl-2 family proteases and thus is the sentinel to protease-mediated death signals. In response to apoptotic signaling, BID interacts with another Bcl-2 family protein, Bax, leading to the insertion of Bax into organelle membranes, primarily the outer mitochondrial membrane. The expression of BID is upregulated by the tumor suppressor p53, and BID has been shown to be involved in p53-mediated apoptosis. Recent studies further indicate that BID may be more than just a killer molecule, it could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint. BID is a key regulator of the intrinsic death pathway that amplifies caspase-dependent and caspase-independent execution of neuronal apoptosis. Therefore pharmacological inhibition of BID provides a promising therapeutic strategy in neurological diseases where programmed cell death is prominent.